Abstract Purpose This Position Paper aims to review and discuss the available data on
therapeutic drug monitoring (TDM) of antibacterials, antifungals and antivirals in critically ill …

Introduction The increasing prevalence of infections with multidrug-resistant (MDR),
extensively-drug resistant (XDR) or difficult-to-treat drug resistant (DTR) Gram-negative …

Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer
therapies are becoming available, it is anticipated that resistance to these agents will …

Polymyxin B (PB) has reemerged as a common treatment against multidrug-resistant Gram-
negative pathogens. However, nephrotoxicity remains a significant dose-limiting side effect …

Currently, polymyxin B has been widely used in the treatment of multidrug-resistant Gram-
negative pathogen infections. Due to the limited pharmacokinetic/pharmacodynamic data …

Objectives Polymyxin B is a last-line antibiotic for multidrug-resistant gram-negative bacterial
infections. However, limited safety and pharmacokinetic information is available. We …

Background The appropriate administration regimen of polymyxin B is yet controversial. The
present study aimed to explore the optimal dose of polymyxin B under therapeutic drug …

Aims Current FDA‐approved label recommends that the dosage of polymyxin B should be
adjusted according to renal function. However, the correlation between polymyxin B …

Polymyxin B is used as a last therapeutic option for the treatment of multidrug-resistant Gram-
negative bacterial infections. This study aimed to develop a population pharmacokinetic …

The polymyxins, colistin (also known as polymyxin E) and polymyxin B, have a unique and
interesting history. Originally introduced in the 1950s for the treatment of infections owing to …